Twist Bioscience Corporation (TWST) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips.
Is Twist Bioscience Corporation stock overvalued or undervalued in 2026?
As of October 2, 2026, Twist Bioscience Corporation (TWST) trades at $188.05 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Twist Bioscience Corporation
Market cap $12B · 52 weeks $25 – $205 (0 % below the high) · P/E no earnings · Dividend none · Next earnings November 13, 2026 · expected EPS $-0.44 · Price as of Oct 2 · accounts published Aug 3.
- Valuation: P/Sales 20.2× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.7 %, fails.
- Market cap / Cash 48.4×, fails.
- Cash Runway 59 meses, passes.
- Total Debt 0.6×, passes.
- Annual cash burn $0.80, info.
Against its peers (reference peers) — Twist Bioscience Corporation: P/E —; EV/EBITDA —; ROIC -24.6 %; $11.7B. Guardian Pharmacy Services, Inc. (P/E 40.4×; EV/EBITDA 19.2×; ROIC 22.9 %; $2.7B), Bio-Techne Corporation (P/E 62.4×; EV/EBITDA 32.1×; ROIC 7.5 %; $11.3B), Halozyme Therapeutics, Inc. (P/E 31.2×; EV/EBITDA 20.8×; ROIC 27.4 %; $12.7B).
Profitability
| Return on Equity | -29.89% |
| Return on Invested Capital | -24.57% |
| Return on Assets | -20.33% |
| Gross Margin | 51.97% |
| Operating Margin | -31.91% |
| Net Margin | -31.66% |
Financial Health
| Debt / Equity | 0.21 |
| Current Ratio | 2.67 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.44 |
Price Performance
| 1 month | +64.37% |
| 3 months | +129.36% |
| Year-to-date | +546.28% |
| 1 year | +543.64% |
| 3 years | +1031.35% |
| 5 years | +104.16% |
Related companies: BGM · CLOV · EWTX · GPCR · GRDN · MESO · PRCT
Explore sector: Healthcare · Biotechnology
More sections of TWST: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks